Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

Table 1

Summary of first- and second-line trials in metastatic pancreatic ductal adenocarcinoma.

Reference	Treatment arms		Primary endpoint	Response rate (%)	Median PFS (months)	Median OS (months)
First-line therapy
Burris et al. [8]	Gemcitabine vs.	126	CBR	23.8	2.1	5.65
	5-FU			4.8	1.2	4.41
	Cunningham et al. [14]			Gemcitabine-capecitabine vs.	533	OS	19.1	5.3	7.1
gemcitabine		12.3	3.8	6.2
			HR 0.78	HR 0.86
PRODIGE4/ACCORD 11 [6]		FOLFIRINOX vs.	342	OS			31.6	6.4	11.1
	gemcitabine	9.4			3.3	6.8
					HR 0.47	HR 0.57
	MPACT [15]	Gemcitabine/nab-paclitaxel vs.			861	OS	23	5.5	8.5
gemcitabine		7	3.7	6.7
			HR 0.69	HR 0.72
Second-line therapy
CONKO-003 [18]	OFF vs.	168	OS	NR	2.9	5.9
	FF				2.0	3.3
					HR 0.68	HR 0.66
	PANCREOX [19]			mFOLFOX6 vs.	108	PFS	13.2	3.1	6.1
5-FU+leucovorin		8.5	2.9	9.9
			HR 1.00	HR 1.78
NAPOLI-1 [21]		Nal-IRI+5-FU/LV vs.	417	OS			17	3.1	6.2
	5-FU/LV	1			1.5	4.2
					HR 0.57	HR 0.75
	Nal-IRI vs.					6	2.7	4.9
	5-FU/LV			1	1.6	4.2
					HR 0.81	HR 1.07

Abbreviations: CBR: clinical benefit response; FF: leucovorin+fluorouracil; HR: hazard ratio; FOLFIRINOX: 5-fluorouracil, irinotecan+oxaliplatin; mFOLFOX6 (modified FOLFOX6): 5-fluorouracil, leucovorin, and oxaliplatin; OFF: oxaliplatin+leucovorin+fluorouracil; LV: leucovorin; Nal-IRI: nanoliposomal irinotecan; OS: overall survival; PFS: progression-free survival; 5-FU: 5-fluorouracil.